期刊
CELL HOST & MICROBE
卷 26, 期 1, 页码 73-+出版社
CELL PRESS
DOI: 10.1016/j.chom.2019.06.005
关键词
-
资金
- NIH [UM1 AI126603, UM1 AI126620, UM1 AI12661, PPG MH070306, NS077869, NS076357, U19-0AI076113, R56 AI118753, 1R01AI127142, T32 GM007445, T32 AI007291-27]
- Howard Hughes Medical Institute
- Bill and Melinda Gates Foundation [OPP1115715]
- NCRR
- Office of Research Infrastructure Programs (ORIP) of the NIH [P40 OD013117]
- National Cancer Institute, NIH [HSN261200800001E]
- NIH/NIAID [AI120765, AI060466]
Evaluation of HIV cure strategies is complicated by defective proviruses that persist in ART-treated patients but are irrelevant to cure. Non-human primates (NHP) are essential for testing cure strategies. However, the persisting proviral landscape in ART-treated NHPs is uncharacterized. Here, we describe viral genomes persisting in ART-treated, simian immunodeficiency virus (SIV)-infected NHPs, simian-human immunodeficiency virus (SHIV)-infected NHPs, and humans infected with HIV-2, an SIV-related virus. The landscapes of persisting SIV, SHIV, and HIV-2 genomes are also dominated by defective sequences. However, there was a significantly higher fraction of intact SIV proviral genomes compared to ART-treated HIV-1 or HIV-2 infected humans. Compared to humans with HIV-1, SIV-infected NHPs had more hypermutated genomes, a relative paucity of clonal SIV sequences, and a lower frequency of deleted genomes. Finally, we report an assay for measuring intact SIV genomes which may have value in cure research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据